OXB vs. HVO, AVCT, BVXP, 4BB, FUM, SCLP, FARN, ETX, POLB, and PRTC
Should you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include hVIVO (HVO), Avacta Group (AVCT), Bioventix (BVXP), 4basebio (4BB), Futura Medical (FUM), Scancell (SCLP), Faron Pharmaceuticals Oy (FARN), e-therapeutics (ETX), Poolbeg Pharma (POLB), and PureTech Health (PRTC). These companies are all part of the "biotechnology" industry.
Oxford Biomedica (LON:OXB) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
hVIVO has lower revenue, but higher earnings than Oxford Biomedica.
hVIVO has a net margin of 4.75% compared to Oxford Biomedica's net margin of -51.78%. hVIVO's return on equity of 13.55% beat Oxford Biomedica's return on equity.
Oxford Biomedica received 235 more outperform votes than hVIVO when rated by MarketBeat users. However, 69.89% of users gave hVIVO an outperform vote while only 66.79% of users gave Oxford Biomedica an outperform vote.
Oxford Biomedica has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, hVIVO has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.
In the previous week, hVIVO had 2 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for hVIVO and 0 mentions for Oxford Biomedica. hVIVO's average media sentiment score of 0.57 beat Oxford Biomedica's score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.
58.1% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 14.0% of hVIVO shares are owned by institutional investors. 16.2% of Oxford Biomedica shares are owned by insiders. Comparatively, 39.2% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Oxford Biomedica presently has a consensus target price of GBX 498.75, suggesting a potential upside of 126.70%. Given Oxford Biomedica's higher probable upside, equities analysts plainly believe Oxford Biomedica is more favorable than hVIVO.
Summary
hVIVO beats Oxford Biomedica on 10 of the 16 factors compared between the two stocks.
Get Oxford Biomedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford Biomedica Competitors List
Related Companies and Tools
